Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
(
1 selected
)
Type
Guidance (298)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (13)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (298)
Apply filters
Showing 151 to 200 of 298
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Mirikizumab for treating moderately to severely active Crohn's disease ID6244
Technology appraisal guidance
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Technology appraisal guidance
TBC
Molnupiravir for treating COVID 19 [ID6340]
Technology appraisal guidance
29 January 2025
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
Technology appraisal guidance
TBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]
Technology appraisal guidance
TBC
Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221
Technology appraisal guidance
TBC
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Technology appraisal guidance
TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
Technology appraisal guidance
28 June 2017
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Technology appraisal guidance
TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Technology appraisal guidance
17 July 2024
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Technology appraisal guidance
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Technology appraisal guidance
TBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Technology appraisal guidance
TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
Technology appraisal guidance
4 December 2024
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
Technology appraisal guidance
TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Technology appraisal guidance
TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Technology appraisal guidance
TBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]
Technology appraisal guidance
TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]
Technology appraisal guidance
25 September 2024
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Technology appraisal guidance
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Technology appraisal guidance
TBC
ONS-5010 for treating wet age-related macular degeneration ID6320
Technology appraisal guidance
TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
Technology appraisal guidance
TBC
OrganOx metra for liver transplant [ID5116]
Technology appraisal guidance
TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]
Technology appraisal guidance
14 August 2024
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
Technology appraisal guidance
TBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Technology appraisal guidance
TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]
Technology appraisal guidance
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Technology appraisal guidance
TBC
Palopegteriparatide for treating chronic hypoparathyroidism ID6380
Technology appraisal guidance
TBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Technology appraisal guidance
TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594
Technology appraisal guidance
TBC
Pegcetacoplan for treating geographic atrophy [ID4041]
Technology appraisal guidance
TBC
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]
Technology appraisal guidance
16 October 2024
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]
Technology appraisal guidance
16 October 2024
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]
Technology appraisal guidance
21 August 2024
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]
Technology appraisal guidance
TBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332
Technology appraisal guidance
TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Technology appraisal guidance
TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Technology appraisal guidance
TBC
Previous page
1
2
3
Current page
4
5
6
Page
4
of
6
Next page
Results per page
10
25
50
All
Back to top